Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03762018 · OUTCOME

Objective Response Rate (ORR)

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma · Source last updated 2026-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From randomization to termination of trial treatment, up to 52 months.

What was measured

Objective Response Rate (ORR) is defined as the percentage of patients that achieve a best overall response \[complete response (CR) or partial response (PR)\] evaluated according to the mRECIST v1.1 across all post-randomization time-points until the end of protocol treatment. Confirmation of response will not be required.

Analysis population: Efficacy population (Intention-To-Treat cohort of all randomised patients)

Groups in this outcome

Atezolizumab Plus Bevacizumab Plus Chemotherapy

Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks

Bevacizumab Plus Chemotherapy

Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab Plus Bevacizumab Plus Chemotherapy200
Bevacizumab Plus Chemotherapy200

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab Plus Bevacizumab Plus Chemotherapy110Not reportedNot reportedNot reportedNot reported
Bevacizumab Plus Chemotherapy98Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        110
      2. group Id
        OG001
        value
        98
denoms
  1. counts
    1. group Id
      OG000
      value
      200
    2. group Id
      OG001
      value
      200
    units
    Participants
description
Objective Response Rate (ORR) is defined as the percentage of patients that achieve a best overall response \[complete response (CR) or partial response (PR)\] evaluated according to the mRECIST v1.1 across all post-randomization time-points until the end of protocol treatment. Confirmation of response will not be required.
groups
  1. description
    Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
    id
    OG000
    title
    Atezolizumab Plus Bevacizumab Plus Chemotherapy
  2. description
    Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
    id
    OG001
    title
    Bevacizumab Plus Chemotherapy
param Type
COUNT_OF_PARTICIPANTS
population Description
Efficacy population (Intention-To-Treat cohort of all randomised patients)
reporting Status
POSTED
time Frame
From randomization to termination of trial treatment, up to 52 months.
title
Objective Response Rate (ORR)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice